Brought to you by 
NuBiyota teams up with Takeda in new GI microbiome deal; Program discontinued
11 Aug 2022
Executive Summary
Takeda Pharmaceutical Co. Ltd. signed its second microbiome deal in less than a week, this time partnering with NuBiyota LLC to discover and develop new therapies for undisclosed gastroenterology conditions.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
NuBiyota teams up with Takeda in new GI microbiome deal; Program discontinued
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice